Skip to main content

and
  1. Article

    Open Access

    Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and Design

    Type 2 diabetes (T2DM) is associated with cardiovascular death, including sudden cardiac death due to arrhythmias. Patients with an implantable cardioverter-defibrillator (ICD) are also at high risk of develop...

    Shinya Fujiki, Kenichi Iijima, Masaaki Okabe, Shinichi Niwano in Diabetes Therapy (2020)

  2. Article

    Open Access

    Late presentation of arrhythmogenic right ventricular cardiomyopathy in an octogenarian associated with a pathogenic variant in the plakophilin 2 gene: a case report

    Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited myocardial disease characterized by fibrofatty replacement and ventricular arrhythmias. ARVC is believed to be a disease of the young, wit...

    Yusuke Adachi, Takekuni Hayashi, Takeshi Mitsuhashi in BMC Cardiovascular Disorders (2019)

  3. No Access

    Article

    Clinical characteristics associated with pacing-induced cardiac dysfunction: a high incidence of undiagnosed cardiac sarcoidosis before permanent pacemaker implantation

    Previous studies suggested that right ventricular pacing was associated with pacing-induced cardiac dysfunction (PICD). The purpose of this study was to investigate the clinical characteristics including the i...

    Yasushi Wakabayashi, Takeshi Mitsuhashi, Naoyuki Akashi in Heart and Vessels (2018)

  4. No Access

    Article

    Clinical background including anticoagulant therapy in patients with atrial fibrillation in a community-based survey: the Saitama AF Registry

    Atrial fibrillation (AF) is one of the most common cardiac arrhythmias, and carries an increased risk of cardiogenic embolism. Oral anticoagulants (OACs) including warfarin and/or non-vitamin K antagonists can...

    Yasushi Wakabayashi, Yoshitaka Sugawara, Kanna Fujita in Heart and Vessels (2017)

  5. No Access

    Article

    Lower 1,5-anhydroglucitol is associated with adverse clinical events after percutaneous coronary intervention

    Diabetes mellitus and impaired glucose tolerance are well-known risk factors for coronary artery disease (CAD) and adverse clinical events after percutaneous coronary intervention (PCI). Postprandial hyperglyc...

    Takayuki Fujiwara, Masashi Yoshida, Naoyuki Akashi, Hodaka Yamada in Heart and Vessels (2016)

  6. No Access

    Article

    Dipeptidyl peptidase-4 inhibitors are associated with improved left ventricular diastolic function after acute myocardial infarction in diabetic patients

    Dipeptidyl peptidase-4 (DPP4) is an integral membrane glycoprotein that modulates the pathological state of diabetes mellitus (DM), and DPP4 inhibitors are a new class of anti-type-2 DM drugs. Recent preclinic...

    Takayuki Fujiwara, Masashi Yoshida, Tomohiro Nakamura in Heart and Vessels (2015)

  7. No Access

    Article

    Lower 1,5-anhydroglucitol is associated with denovo coronary artery disease in patients at high cardiovascular risk

    Postprandial hyperglycemia is a risk factor for cardiovascular disease and mortality. Serum 1,5-anhydroglucitol (1,5-AG) level is an useful clinical marker of glucose metabolism which reflects postprandial hyp...

    Takayuki Fujiwara, Masashi Yoshida, Hodaka Yamada, Takunori Tsukui in Heart and Vessels (2015)

  8. Article

    Open Access

    Prognosis of patients with fulminant myocarditis managed by peripheral venoarterial extracorporeal membranous oxygenation support: a retrospective single-center study

    Peripheral venoarterial extracorporeal membranous oxygenation (ECMO) support is effective in patients with cardiogenic shock or fatal arrhythmia due to fulminant myocarditis. The clinical courses of fulminant ...

    Tomohiro Nakamura, Kohki Ishida, Yousuke Taniguchi in Journal of Intensive Care (2015)